World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   140 records for 67 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7
Recruitment statusMain ID Public TitleDate of Registration
Not recruitingNCT02535026
An Observational Study on HER2 Status of Breast Invasive Carcinoma in Latin American Participants
26/08/2015
Not recruitingNCT02326857
Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment
25/12/2014
RecruitingNCT02307201
Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia
24/11/2014
RecruitingNCT02189538
Effect of n-3 PUFA From Fish in Enteral Nutrition of Major Burn Patients
03/07/2014
Not recruitingNCT02132897
Fed Bioequivalence Study of CBZ Formulations
06/05/2014
RecruitingNCT02011334
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
04/12/2013
RecruitingNCT01966471
A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-004902-82-GBA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.21/11/2013
AuthorisedEUCTR2012-004902-82-CZA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.25/11/2013
AuthorisedEUCTR2012-004902-82-HUA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.22/11/2013
Not RecruitingEUCTR2012-004902-82-ITA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.18/11/2013
Not RecruitingEUCTR2012-004902-82-ESA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.05/12/2013
AuthorisedEUCTR2012-004902-82-SEA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.23/12/2013
AuthorisedEUCTR2012-004902-82-BEA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.18/12/2013
Not RecruitingJPRN-JapicCTI-142421Phase III clinical trial of trastuzumab emtansine and pertuzumab in patients with early breast cancer07/07/2015
Not RecruitingEUCTR2012-004902-82-DEA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.22/11/2013
AuthorisedEUCTR2012-004902-82-PLA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.23/04/2014
AuthorisedEUCTR2012-004902-82-FRA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.17/06/2015
17/10/2013
RecruitingNCT01970189
The International ITP Registry
19/09/2013
AuthorisedEUCTR2013-000087-29-IT
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000087-29-SIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.03/09/2013
AuthorisedEUCTR2013-000087-29-LVInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.02/09/2013
AuthorisedEUCTR2013-000087-29-GRInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.21/10/2013
AuthorisedEUCTR2013-000087-29-ESInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.12/07/2013
AuthorisedEUCTR2013-000087-29-SEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.29/10/2013
AuthorisedEUCTR2013-000087-29-BEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.13/01/2014
AuthorisedEUCTR2013-000087-29-PTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/09/2013
AuthorisedEUCTR2013-000087-29-EEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.10/10/2013
AuthorisedEUCTR2013-000087-29-PLInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.04/11/2013
AuthorisedEUCTR2013-000087-29-DEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.08/07/2013
AuthorisedEUCTR2013-000087-29-IEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukaemia.12/09/2013
AuthorisedEUCTR2013-000087-29-LTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.28/01/2014
AuthorisedEUCTR2013-000087-29-FIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/07/2013
RecruitingNCT01905943A Safety Study of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia19/07/2013
02/07/2013
RecruitingNCT01881659
Cervical Cancer Screening With Human Papillomavirus Testing
17/06/2013
    
1 2 3 4 5 6 7
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history